Mount Sinai's Knowledge Management Center for Illuminating the Druggable Genome

位于西奈山的照亮可药物基因组的知识管理中心(KMC-IDG)将 组装、组织和可视化从四个正在研究的可药物基因组中收集的数据 家族：蛋白激酶、核受体、离子通道和GPCRs。KMC-IDG还将尝试链接 这些未被研究的药物靶点可能在各种疾病中应用。为了实现这一目标，我们 将从四个领域收集和提取数据：蛋白质/基因/靶点，药物/干扰物， 疾病/表型/副作用，以及来自个别患者的数据。各种管道和工作流程将被 建立的目的是将来自不同疾病的患者群与研究不足的可用药靶点联系起来。这个 Ma‘ayan和Dudley实验室处于有利地位，可以根据他们之前的轨迹成功地实施这个项目 已收集和组织的生产力、源代码和数据的基础，以及强大的记录 可以定向到新开发的门户网站的现有用户群。此外，两个实验室都有很强的 合作的跟踪记录，包括至少计算确定和实验验证 一种未被研究的蛋白激酶作为减轻肾脏纤维化的潜在重要靶点。独一无二的 本项目的创新研究部分是对文献来源和 存在于分子和细胞生物学研究领域的实验偏见。

The Knowledge Management Center for Illuminating the Druggable Genome (KMC-IDG) at Mount Sinai will assemble, organize and visualize data collected from the under-studied druggable genome from the four families: protein kinases, nuclear receptor, ion channels and GPCRs. The KMC-IDG will also attempt linking such under-studied druggable targets for their potential applications in various diseases. To achieve this we will assemble and abstract data from four domains: proteins/genes/targets, drugs/perturbagens, diseases/phenotypes/side-effects, and data from individual patients. Various pipe-lines and workflow will be established to connect clusters of patients from various diseases to under-studied druggable targets. The Ma'ayan and Dudley Labs are well positioned to carry out successfully this project based on their prior track record of productivity, foundation of source code and data that is already collected and organized, and strong existing user base that can be directed to the newly developed portal. In addition, both labs have a strong track record of collaborations including the computational identification and experimental validation of at least one under-studied protein kinase as a potential important target for attenuating kidney fibrosis. One unique and innovative research component of this project is an investigation into the sources of the literature and experimental biases that exist in the molecular and cellular biology research domains.